Noyada (captopril): Reviews and patient testimonials

Noyada 25mg/5ml Oral Solution

Hypertension: Noyada oral solution is indicated for the treatment of hypertension.

Heart Failure: Noyada oral solution is indicated for the treatment of chronic heart failure with reduction of systolic ventricular function, in combination with diuretics and, when appropriate, digitalis and beta-blockers.

Myocardial Infarction:

- short-term (4 weeks) treatment: Noyada oral solution is indicated in any clinically stable patient within the first 24 hours of an infarction.

- long-term prevention of symptomatic heart failure: Noyada oral solution is indicated in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction equal to or below 40%).

Type I Diabetic Nephropathy: Noyada oral solution is indicated for the treatment of macroproteinuric diabetic nephropathy in patients with type I diabetes. (See section 5.1).

Noyada oral solution can be used alone or in combination with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1).

Noyada 5mg/5ml Oral Solution

Hypertension: Noyada oral solution is indicated for the treatment of hypertension.

Heart Failure: Noyada oral solution is indicated for the treatment of chronic heart failure with reduction of systolic ventricular function, in combination with diuretics and, when appropriate, digitalis and beta-blockers.

Myocardial Infarction:

- short-term (4 weeks) treatment: Noyada oral solution is indicated in any clinically stable patient within the first 24 hours of an infarction.

- long-term prevention of symptomatic heart failure: Noyada oral solution is indicated in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction equal to or below 40%).

Type I Diabetic Nephropathy: Noyada oral solution is indicated for the treatment of macroproteinuric diabetic nephropathy in patients with type I diabetes. (See section 5.1).

Noyada oral solution can be used alone or in combination with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1).